Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Correction

Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study

Authors: Monica Niger, Federico Nichetti, Lorenzo Fornaro, Chiara Pircher, Federica Morano, Federica Palermo, Lorenza Rimassa, Tiziana Pressiani, Rossana Berardi, Andrea Casadei Gardini, Elisa Sperti, Lisa Salvatore, Davide Melisi, Francesca Bergamo, Salvatore Siena, Stefania Mosconi, Rafaella Longarini, Giuseppina Arcangeli, Salvatore Corallo, Laura Delliponti, Stefano Tamberi, Elena Fea, Giovanni Brandi, Ilario Giovanni Rapposelli, Massimiliano Salati, Paolo Baili, Rosalba Miceli, Silva Ljevar, Ilaria Cavallo, Elisa Sottotetti, Antonia Martinetti, Michele Droz Dit Busset, Carlo Sposito, Maria Di Bartolomeo, Filippo Pietrantonio, Filippo de Braud, Vincenzo Mazzaferro

Published in: BMC Cancer | Issue 1/2024

Login to get access

Excerpt

Correction to: BMC Cancer 24, 436 (2024)
Literature
Metadata
Title
Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study
Authors
Monica Niger
Federico Nichetti
Lorenzo Fornaro
Chiara Pircher
Federica Morano
Federica Palermo
Lorenza Rimassa
Tiziana Pressiani
Rossana Berardi
Andrea Casadei Gardini
Elisa Sperti
Lisa Salvatore
Davide Melisi
Francesca Bergamo
Salvatore Siena
Stefania Mosconi
Rafaella Longarini
Giuseppina Arcangeli
Salvatore Corallo
Laura Delliponti
Stefano Tamberi
Elena Fea
Giovanni Brandi
Ilario Giovanni Rapposelli
Massimiliano Salati
Paolo Baili
Rosalba Miceli
Silva Ljevar
Ilaria Cavallo
Elisa Sottotetti
Antonia Martinetti
Michele Droz Dit Busset
Carlo Sposito
Maria Di Bartolomeo
Filippo Pietrantonio
Filippo de Braud
Vincenzo Mazzaferro
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12328-0

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine